Alanine aminotransferase/aspartate aminotransferase ratio is the best surrogate marker for insulin resistance in non-obese Japanese adults

Cardiovascular Diabetology

Volumn 11, Issue , 2012, Pages

  Kawamoto, Ryuichi ^a,c   Kohara, Katsuhiko ^a   Kusunoki, Tomo ^a   Tabara, Yasuharu ^b   Abe, Masanori ^a   Miki, Tetsuro ^a  

^a EHIME UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c Seiyo Municipal Nomura Hospital   (Japan)

Author keywords

ALT AST ratio; Body mass index; Insulin resistance; Marker

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; INSULIN;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BODY MASS; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; DISEASE MARKER; FEMALE; HUMAN; INSULIN RESISTANCE; JAPANESE; MAJOR CLINICAL STUDY; MALE; OBESITY; RECEIVER OPERATING CHARACTERISTIC;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ALANINE TRANSAMINASE; AREA UNDER CURVE; ASIAN CONTINENTAL ANCESTRY GROUP; ASPARTATE AMINOTRANSFERASES; BIOLOGICAL MARKERS; BODY MASS INDEX; CHI-SQUARE DISTRIBUTION; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; INSULIN RESISTANCE; JAPAN; LIKELIHOOD FUNCTIONS; LINEAR MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PREDICTIVE VALUE OF TESTS; ROC CURVE; YOUNG ADULT;

EID: 84866779019     PISSN: None     EISSN: 14752840     Source Type: Journal    
DOI: 10.1186/1475-2840-11-117     Document Type: Article

References (37)

1. Gallagher EJ, Leroith D, Karnieli E. Insulin resistance in obesity as the underlying cause for the metabolic syndrome. Mt Sinai J Med 2010, 77:511-523. 10.1002/msj.20212, 20960553.
2. DeFronzo RA, Ferrannini E. Insulin resistance: a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 1991, 14:173-194. 10.2337/diacare.14.3.173, 2044434.
3. Fontbonne AM, Eschwege EM. Insulin and cardiovascular disease: Paris prospective study. Diabetes Care 1991, 14:461-469. 10.2337/diacare.14.6.461, 1864219.
4. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet 2005, 365:1415-1428. 10.1016/S0140-6736(05)66378-7, 15836891.
5. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985, 28:412-419. 10.1007/BF00280883, 3899825.
6. Meisinger C, Löwel H, Heier M, Schneider A, Thorand B, KORA Study Group Serum gamma-glutamyltransferase and risk of type 2 diabetes mellitus in men and women from the general population. J Intern Med 2005, 258:527-535. 10.1111/j.1365-2796.2005.01572.x, 16313476, KORA Study Group.
7. Wannamethee SG, Shaper AG, Lennon L, Whincup PH. Hepatic enzymes, the metabolic syndrome, and the risk of type 2 diabetes in older men. Diabetes Care 2005, 28:2913-2918. 10.2337/diacare.28.12.2913, 16306554.
8. Doi Y, Kubo M, Yonemoto K, Ninomiya T, Iwase M, Tanizaki Y, Shikata K, Iida M, Kiyohara Y. Liver enzymes as a predictor for incident diabetes in a Japanese population: the Hisayama study. Obesity (Silver Spring) 2007, 15:1841-1850.
9. Monami M, Bardini G, Lamanna C, Pala L, Cresci B, Francesconi P, Buiatti E, Rotella CM, Mannucci E. Liver enzymes and risk of diabetes and cardiovascular disease: results of the Firenze Bagno a Ripoli (FIBAR) study. Metabolism 2008, 57:387-392. 10.1016/j.metabol.2007.10.015, 18249212.
10. Gao F, Pan JM, Hou XH, Fang QC, Lu HJ, Tang JL, Gu HL, Pan ZJ, Yao YH, Shen WZ, Jia WP. Liver enzyme concentrations are closely related to prediabetes: findings of the Shanghai Diabetes Study II (SHDS II). Biomed Environ Sci 2012, 25:30-37.
11. André P, Balkau B, Vol S, Charles MA, Eschwège E, DESIR Study Group Gamma-glutamyltransferase activity and development of the metabolic syndrome (International Diabetes Federation Definition) in middle-aged men and women: Data from the Epidemiological Study on the Insulin Resistance Syndrome (DESIR) cohort. Diabetes Care 2007, 30:2355-2361. 10.2337/dc07-0440, 17586745, DESIR Study Group.
12. Xu Y, Bi YF, Xu M, Huang Y, Lu WY, Gu YF, Ning G, Li XY. Cross-sectional and longitudinal association of serum alanine aminotransaminase and γ-glutamyltransferase with metabolic syndrome in middle-aged and elderly Chinese people. J Diabetes 2011, 3:38-47. 10.1111/j.1753-0407.2010.00111.x, 21199427.
13. Steinvil A, Shapira I, Ben-Bassat OK, Cohen M, Vered Y, Berliner S, Rogowski O. The association of higher levels of within-normal-limits liver enzymes and the prevalence of the metabolic syndrome. Cardiovasc Diabetol 2010, 9:30. 10.1186/1475-2840-9-30, 2915953, 20633271.
14. Sookoian S, Pirola CJ. Alanine and aspartate aminotransferase and glutamine-cycling pathway: Their roles in pathogenesis of metabolic syndrome. World J Gastroenterol 2012, 18:3775-3781. 10.3748/wjg.v18.i29.3775, 3413046, 22876026.
15. Vozarova B, Stefan N, Lindsay RS, Saremi A, Pratley RE, Bogardus C, Tataranni PA. High alanine aminotransferase is associated with decreased hepatic insulin sensitivity and predicts the development of type 2 diabetes. Diabetes 2002, 51:1889-1895. 10.2337/diabetes.51.6.1889, 12031978.
16. Ortega E, Koska J, Salbe AD, Tataranni PA, Bunt JC. Serum gamma-glutamyl transpeptidase is a determinant of insulin resistance independently of adiposity in Pima Indian children. J Clin Endocrinol Metab 2006, 91:1419-1422. 10.1210/jc.2005-1783, 16434459.
17. Kawamoto R, Tabara Y, Kohara K, Miki T, Kusunoki T, Takayama S, Abe M, Katoh T, Ohtsuka N. High-sensitivity C-reactive protein and gamma-glutamyl transferase levels are synergistically associated with metabolic syndrome in community-dwelling persons. Cardiovasc Diabetol 2010, 9:87. 10.1186/1475-2840-9-87, 3014885, 21143879.
18. Kawamoto R, Kohara K, Tabara Y, Miki T. An association between metabolic syndrome and the estimated glomerular filtration rate. Intern Med 2008, 47:1399-1406. 10.2169/internalmedicine.47.1202, 18670145.
19. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972, 18:499-502.
20. Yeni-Komshian H, Carantoni M, Abbasi F, Reaven GM. Relationship between several surrogate estimates of insulin resistance and quantification of insulin-mediated glucose disposal in 490 healthy nondiabetic volunteers. Diabetes Care 2000, 23:171-175. 10.2337/diacare.23.2.171, 10868826.
21. Taniguchi A, Fukushima M, Sakai M, Kataoka K, Miwa K, Nagata I, Doi K, Tokuyama K, Nakai Y. Insulin-sensitive and insulin-resistant variants in nonobese Japanese type 2 diabetic patients. The role of triglycerides in insulin resistance. Diabetes Care 1999, 22:2100-2101. 10.2337/diacare.22.12.2100, 10587863.
22. Bonora E, Kiechl S, Willeit J, Oberhollenzer F, Egger G, Targher G, Alberiche M, Bonadonna RC, Muggeo M. Prevalence of insulin resistance in metabolic disorders: the Bruneck Study. Diabetes 1998, 47:1643-1649. 10.2337/diabetes.47.10.1643, 9753305.
23. Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modeling. Diabetes Care 2004, 27:1487-1495. 10.2337/diacare.27.6.1487, 15161807.
24. Kim-Dorner SJ, Deuster PA, Zeno SA, Remaley AT, Poth M. Should triglycerides and the triglycerides to high-density lipoprotein cholesterol ratio be used as surrogates for insulin resistance?. Metabolism 2010, 59:299-304. 10.1016/j.metabol.2009.07.027, 19796777.
25. Kannel WB, Vasan RS, Keyes MJ, Sullivan LM, Robins SJ. Usefulness of the triglyceride-high-density lipoprotein versus the cholesterol-high-density lipoprotein ratio for predicting insulin resistance and cardiometabolic risk (from the Framingham Offspring Cohort). Am J Cardiol 2008, 101:497-501. 10.1016/j.amjcard.2007.09.109, 18312765.
26. Tamada M, Makita S, Abiko A, Naganuma Y, Nagai M, Nakamura M. Low-density lipoprotein cholesterol to high-density lipoprotein cholesterol ratio as a useful marker for early-stage carotid atherosclerosis. Metabolism 2010, 59:653-657. 10.1016/j.metabol.2009.09.009, 19913853.
27. Kimm H, Lee SW, Lee HS, Shim KW, Cho CY, Yun JE, Jee SH. Associations between lipid measures and metabolic syndrome, insulin resistance and adiponectin. - Usefulness of lipid ratios in Korean men and women. Circ J 2010, 74:931-937. 10.1253/circj.CJ-09-0571, 20215701.
28. Kawamoto R, Tabara Y, Kohara K, Miki T, Kusunoki T, Takayama S, Abe M, Katoh T, Ohtsuka N. Relationships between lipid profiles and metabolic syndrome, insulin resistance and serum high molecular adiponectin in Japanese community-dwelling adults. Lipids Health Dis 2011, 10:79. 10.1186/1476-511X-10-79, 3118370, 21586120.
29. Ioannou GN, Weiss NS, Boyko EJ, Kahn SE, Lee SP. Contribution of metabolic factors to alanine aminotransferase activity in persons with other causes of liver disease. Gastroenterology 2005, 128:627-635. 10.1053/j.gastro.2004.12.004, 15810122.
30. Hanley AJ, Wagenknecht LE, Festa A, D'Agostino RB, Haffner SM. Alanine aminotransferase and directly measured insulin sensitivity in a multiethnic cohort: the Insulin Resistance Atherosclerosis Study. Diabetes Care 2007, 30:1819-1827. 10.2337/dc07-0086, 17429060.
31. Homsanit M, Sanguankeo A, Upala S, Udol K. Abnormal liver enzymes in Thai patients with metabolic syndromes. J Med Assoc Thai 2012, 95:444-451.
32. Seppälä-Lindroos A, Vehkavaara S, Häkkinen AM, Goto T, Westerbacka J, Sovijärvi A, Halavaara J, Yki-Järvinen H. Fat accumulation in the liver is associated with defects in insulin suppression of glucose production and serum free fatty acids independent of obesity in normal men. J Clin Endocrinol Metab 2002, 87:3023-3028. 10.1210/jc.87.7.3023, 12107194.
33. Browning JD, Szczepaniak LS, Dobbins R, Nuremberg P, Horton JD, Cohen JC, Grundy SM, Hobbs HH. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004, 40:1387-1395. 10.1002/hep.20466, 15565570.
34. Nanji AA, French SW, Freeman JB. Serum alanine aminotransferase to aspartate aminotransferase ratio and degree of fatty liver in morbidly obese patients. Enzyme 1986, 36:266-269.
35. Marchesini G, Brizi M, Bianchi G, Tomassetti S, Bugianesi E, Lenzi M, McCullough AJ, Natale S, Forlani G, Melchionda N. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes 2001, 50:1844-1850. 10.2337/diabetes.50.8.1844, 11473047.
36. Mulhall BP, Ong JP, Younossi ZM. Non-alcoholic fatty liver disease: an overview. J Gastroenterol Hepatol 2002, 17:1136-1143. 10.1046/j.1440-1746.2002.02881.x, 12453271.
37. Schindhelm RK, Diamant M, Dekker JM, Tushuizen ME, Teerlink T, Heine RJ. Alanine aminotransferase as a marker of non-alcoholic fatty liver disease in relation to type 2 diabetes mellitus and cardiovascular disease. Diabetes Metab Res Rev 2006, 22:437-443. 10.1002/dmrr.666, 16832839.